Bio Elpida Acquisition Brings GMP Fill and Finish Capacity to Polyplus.
Polyplus, a leading solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has completed the acquisition of Bio Elpida, a French biotechnology contract development and manufacturing (CDMO) company providing pre-clinical and clinical development services for cell therapy and biologics. The teams will integrate strategically to strengthen the supply chain for GMP formulation and filling at Polyplus.